S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

$23.74
-2.61 (-9.90%)
(As of 02/28/2024 ET)
Today's Range
$23.36
$25.17
50-Day Range
$24.78
$31.77
52-Week Range
$17.71
$33.99
Volume
4.83 million shs
Average Volume
1.66 million shs
Market Capitalization
$3.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.26

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
52.7% Upside
$36.26 Price Target
Short Interest
Bearish
5.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$391,705 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to $1.04 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.38 out of 5 stars

Medical Sector

323rd out of 958 stocks

Pharmaceutical Preparations Industry

142nd out of 419 stocks


ACAD stock logo

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

ACAD Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ACADIA Pharmaceuticals (ACAD) Set to Announce Earnings on Tuesday
ACAD Jun 2024 27.000 call
ACAD Mar 2024 30.000 call
ACAD Mar 2024 14.000 call
ACAD Mar 2024 17.000 put
Acadia falls on Culper short
3 Pharma Stocks to Buy for February Gains
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
2/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACAD
Employees
580
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.26
High Stock Price Target
$95.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+52.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-20.83%

Debt

Sales & Book Value

Annual Sales
$517.23 million
Book Value
$2.47 per share

Miscellaneous

Free Float
119,031,000
Market Cap
$3.90 billion
Optionable
Optionable
Beta
0.45
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives















ACAD Stock Analysis - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price target for 2024?

15 Wall Street research analysts have issued 12 month price objectives for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $15.00 to $95.00. On average, they predict the company's share price to reach $36.26 in the next year. This suggests a possible upside of 52.7% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2024?

ACADIA Pharmaceuticals' stock was trading at $31.31 at the start of the year. Since then, ACAD stock has decreased by 24.2% and is now trading at $23.7450.
View the best growth stocks for 2024 here
.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in February. As of February 15th, there was short interest totaling 9,420,000 shares, an increase of 22.7% from the January 31st total of 7,680,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is currently 5.3 days.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by $0.04. The biopharmaceutical company earned $231.04 million during the quarter, compared to analysts' expectations of $223.79 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 38.84% and a negative net margin of 23.55%. ACADIA Pharmaceuticals's revenue for the quarter was up 69.3% on a year-over-year basis. During the same period last year, the company posted ($0.26) earnings per share.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.16%), RTW Investments LP (6.85%), Price T Rowe Associates Inc. MD (3.15%), Palo Alto Investors LP (1.47%), First Trust Advisors LP (1.08%) and Norges Bank (0.88%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACAD) was last updated on 2/29/2024 by MarketBeat.com Staff